| Recruiting | Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Out Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Hypopharynx | — | 2024-11-07 |
| Recruiting | AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT Advanced Solid Tumor | — | 2022-12-08 |
| Completed | Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorec Colorectal Cancer, Colon Cancer, BRAF V600E | Phase 2 | 2022-09-01 |
| Withdrawn | Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus P NSCLC Stage IV | Phase 2 | 2022-05-20 |
| Active Not Recruiting | D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer Chemo-refractory Colorectal Carcinoma | Phase 1 / Phase 2 | 2022-02-17 |
| Active Not Recruiting | Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study NSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression | Phase 2 | 2022-01-20 |
| Active Not Recruiting | Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Ox Colorectal Cancer | Phase 2 | 2021-12-10 |
| Completed | Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma Anemia, Iron Deficiency, Solid Tumor, Malignant Lymphoma | — | 2021-10-25 |
| Terminated | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 | 2021-07-08 |
| Completed | Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients Secondary Immunodeficiencies (SID) | — | 2020-01-28 |
| Completed | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide SCLC, Extensive Stage | Phase 2 | 2020-01-06 |
| Completed | A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of Head and Neck | Phase 2 | 2018-07-16 |
| Completed | Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer Non-small Cell Lung Cancer (NSCLC) | Phase 2 | 2018-06-18 |
| Completed | Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma, Hepatocellular, Hepatic Carcinoma, Hepatocellular Cancer | Phase 2 | 2018-06-14 |
| Completed | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Met Adenocarcinoma of the Lung | Phase 1 / Phase 2 | 2018-05-25 |
| Completed | Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable | Phase 2 | 2018-05-02 |
| Completed | 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Th Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 3 | 2018-03-31 |
| Completed | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarci Gastric Cancer, Esophageal Cancer, Adenocarcinoma Gastric | Phase 2 | 2018-03-01 |
| Completed | A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly P Esophageal Cancer, Oesophageal Cancer, Oesophageal Cancer Metastatic | Phase 2 | 2018-02-21 |
| Terminated | Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head a Cancer of Head and Neck | Phase 2 | 2018-02-02 |
| Completed | Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Canc Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract | Phase 2 | 2018-01-24 |
| Terminated | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequent Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | 2018-01-02 |
| Completed | Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcom Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | 2017-12-15 |
| Completed | Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) Carcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | 2017-12-14 |
| Completed | Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated Wit Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Cholangiocarcinoma of the Gallbladder | Phase 2 | 2017-10-24 |
| Completed | Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed Afte Pretreated Metastatic Colorectal Cancer | Phase 1 | 2017-07-31 |
| Completed | Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Metastatic Colorectal Cancer | Phase 2 | 2017-07-17 |
| Unknown | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carci Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer | Phase 2 | 2017-07-06 |
| Completed | mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer Rectal Cancer, Rectosigmoid Cancer | Phase 2 | 2017-03-06 |
| Completed | Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC Carcinoma，Non-Small-Cell Lung, Metastatic Lung Cancer, Nonsmall Cell Lung Cancer | Phase 2 | 2017-02-10 |
| Terminated | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent | Phase 3 | 2017-01-18 |
| Completed | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine Metastatic Pancreatic Cancer, Adenocarcinoma of the Pancreas | Phase 2 | 2016-12-01 |
| Terminated | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued Wit Metastatic Renal Cell Carcinoma | Phase 2 | 2016-12-01 |
| Completed | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma | Phase 2 | 2016-10-01 |
| Completed | Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Pa Adenocarcinoma Pancreas | Phase 4 | 2016-06-01 |
| Terminated | Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients Venous Thromboembolism, Cancer | Phase 3 | 2016-03-23 |
| Terminated | Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastati Metastatic Squamous Non-small Cell Lung Cancer | Phase 2 | 2016-01-19 |
| Recruiting | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Pa Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage II | — | 2015-12-01 |
| Terminated | Maintaining ERBB Blockade in EGFR-mutated Lung Cancer Non-small-cell Lung Cancer With Somatic EGFR Mutations | Phase 2 | 2015-11-01 |
| Terminated | Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Non-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA, Non-squamous Non-small Cell Lung Cancer Stage IIIB | Phase 2 / Phase 3 | 2015-11-01 |
| Completed | Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stoma Adenocarcinoma,Stomach, Adenocarcinoma, Esophagogastric Junction | Phase 1 / Phase 2 | 2015-10-06 |
| Terminated | A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Breast Cancer, Lung Cancer, Recurrent Brain Metastases | Phase 2 | 2015-08-01 |
| Completed | Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcino Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Phase 2 | 2015-08-01 |
| Completed | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Resectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas | Phase 2 | 2015-07-01 |
| Completed | Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Ductal Adenocarcinoma of the Pancreas | Phase 2 | 2014-11-01 |
| Completed | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2014-09-01 |
| Completed | Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction Aft Metastatic Colorectal Cancer | Phase 2 | 2014-04-01 |
| Terminated | Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Esophageal Squamous Cell Cancer | Phase 3 | 2012-05-01 |
| Completed | Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer | Phase 2 | 2012-01-01 |
| Completed | Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach | Phase 2 | 2011-12-01 |
| Completed | Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas Gastric Adenocarcinoma With Peritoneal Carcinomatosis, Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis, Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis | Phase 2 | 2011-10-01 |
| Completed | Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL Ras-wildtype Colorectal Cancer | Phase 2 | 2011-05-01 |
| Completed | FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) Metastatic Colorectal Cancer | Phase 2 | 2011-04-01 |
| Completed | ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction Stomach Neoplasms, Gastroesophageal Junction Neoplasms | Phase 2 | 2010-10-01 |
| Completed | Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Ga Malignant Ascites, Gastrointestinal Cancers | Phase 2 | 2010-02-01 |
| Terminated | Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Can Colorectal Neoplasms | Phase 2 | 2009-09-01 |
| Completed | Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC) Colorectal Neoplasms | Phase 3 | 2009-08-01 |
| Terminated | Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Li Colorectal Neoplasms | Phase 2 | 2009-03-01 |
| No Longer Available | A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecit the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine | — | — |